Table 1.
Clinical information of 33 advanced colorectal cancer patients (n = 33).
| Characteristics | Statistics |
|---|---|
| Sex (male/female) | 15/18 |
| Age (years) | 53.64 ± 10.34 |
| ECOG (0/1) | 10/23 |
| Primary tumor location (left/right) | 23/10 |
| Liver metastases (yes/no) | 20/13 |
| Lung metastases (yes/no) | 28/5 |
| Lymph node metastasis (yes/no) | 22/11 |
| Excision of primary lesion (yes/no) | 29/4 |
| Number of previous chemotherapy lines | |
| (2/3 lines or above) | 16/17 |
| Regorafenib (80 mg/120 mg) | 23/10 |
| KRAS genetic testing (yes/no) | 21/12 |
| KRAS (wild/mutation) | 13/8 |
|
| |
| Previous chemotherapeutic drug | |
| Fluorouracil (yes/no) | 33/0 |
| Oxaliplatin (yes/no) | 33/0 |
| Irinotecan (yes/no) | 33/0 |
| Raltitrexed (yes/no) | 12/21 |
|
| |
| Previously targeted drugs | |
| Bevacizumab (yes/no) | 28/5 |
| Cetuximab (yes/no) | 11/22 |
ECOG, Eastern Cooperative Oncology Group performance status.